Breast Cancer: SWOG E1199 (Iowa Cancer Specialists)

SWOG E1199: A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks to Patients with Axillary Node-Positive or High Risk Node-Negative Breast Cancer.

Objective

The purpose of the study is to determine whether docetaxel improves disease-free survival and overall survival when compared to paclitaxel following 4 cycles of doxorubicin-cyclophosphamide therapy in women with axillary node-positive and high risk axillary node-negative breast cancer.

Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Sponsor(s)
SWOG
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Cancer Care Institute
    1351 West Central Park
    Pavilion 1, 1st Floor
    Davenport, IA 52804
    Main: 563-421-1900
    Alternate: 800-446-6088
    Fax: 563-421-1938

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email